CDK1 and prostate carcinoma: Mechanism studies have shown that matrine, one of the main ingredients of CKI, exhibits time-dependent inhibition of CDK1 expression in prostate cancer cells, resulting in o cell cycle arrest in the G0/G1 phase, thereby inhibiting cancer cell proliferation [66].